Medical Applications of Evolutionary Computation

Stephen L. Smith
University of York
York, UK
stephen.smith@york.ac.uk

http://www.sigevo.org/gecco-2015/

1

Welcome

- **Stephen L. Smith** received a BSc in Computer Science and then an MSc and PhD in Electronic Engineering from the University of Kent, UK. He is currently a Reader in the Department of Electronics at the University of York, UK.
- Steve's main research interests are in developing novel representations of evolutionary algorithms particularly with application to problems in medicine. His work is currently centered on the diagnosis of neurological dysfunction and analysis of mammograms.
- Steve is co-founder and organizer of the MedGEC Workshop, which is now in its ninth year. He is also co-editor of a book on the subject (John Wiley, November 2010).
- Steve is associate editor for the journal Genetic Programming and Evolvable Machines and a member of the editorial board for the International Journal of Computers in Healthcare and Neural Computing and Applications.
- In 2013 Steve co-founded ClearSky Medical Diagnostics, a university spinout company for developing medical devices that exploit genetic programing technologies.

ClearSky
medical diagnostics

UNIVERSITY *of York*

2

The City of York

3

The University of York

4

The University of York

Overview

❖Introduction to medical applications of EC
  • how these differ from other real-world applications
❖Overview of previous work
  • from a medical and EC point of view
❖Case examples of medical applications
❖Practical advice on how to get started
  • choosing an application and obtaining good data
❖Summary

Introduction

❖Challenging application area
  • often no reliable "ground truth" or "gold standard"
  • access to data difficult
  • multiple ethical considerations
❖Opportunities
  • unexplored territory
  • funding and publications
  • make a difference

Previous Work

❖Medical Imaging and Signal Processing
❖Data Mining Medical Data and Patient Records
❖Modelling and Simulation of Medical Processes
❖Clinical Expert Systems and Knowledge-based Systems
❖Clinical Diagnosis and Therapy

Medical Imaging and Signal Processing
Ballerini and Bocchi [1]

❖Automated image segmentation

❖Bone age assessment
  • to detect abnormality in skeletal growth

❖Multiple genetic snakes
  • planar active contours optimised by GAs
  • elastic force connects adjacent snakes

9

Medical Imaging and Signal Processing
Mañana, González and Romero [2]

❖Image Registration

❖Intra-oral radiographs

❖Distributed adaptive GA
  • to find an optimal affine

❖Genome
  • 4 floating point numbers
    –scale factor
    –rotational angle
    –X &Y translations

10

Data Mining Medical Data and Patient Records
Ghannad-Rezaie et al. [3]

❖Surgery candidate selection
  • for temporal lobe epilepsy
  • integrates a classifier with a particle swarm algorithm (PSO)

❖Compared with:
  • ant colony optimisation (ACO)
  • Bayesian Belief Network (BBN)
  • C4.5 (a decision tree approach)
  • LOcal LInear MOdel Tree (LOLIMOT)

11

Modelling and Simulation of Medical Processes
Bosman and Alderliesten [4]

❖Medical simulation
  • for minimally invasive vascular intervention
  • used to train clinicians

❖Minimisation of energy
  • associated with trajectory of guide wire
  • iterative density estimation evolutionary
  • accurate and closer to real-time simulation of the intervention

12

Clinical Expert Systems and Knowledge-based Systems
Koutsojannis and Hatzilygeroudis [5]

❖ Diagnosis and treatment of blood gas disturbances
  • observed in intensive care unit patients
❖ Fuzzy expert system incorporating an EA
  • differential EA fine-tunes membership functions of the fuzzy variables

13

Why Consider a Medical Application?

❖ Interesting
  • real problems
  • potential to help real people
  • cross-disciplinary collaborations
❖ Good source of funding
  • government
  • charities
  • commercialization opportunities
❖ Good for publications
  • exploit both engineering and medical literatures

14

Choosing a Medical Application

❖ Review the field
  • through the medical and engineering literature
❖ Choose a *novel* application area
  • with a clinical need (medical or financial!)
❖ Contact a health professional
  • go and talk to them
❖ Evaluate the scope for obtaining data
  • and a "gold standard" or "ground truth"

15

Datasets

❖ The performance of any evolutionary algorithm is only as good as the data it is trained on
  • often no definitive clinical test for condition under investigation
  • datasets usually involve subjective clinical assessment
  • often have missing or corrupted values
    – resulting in insufficient good data for statistical
    – can be ameliorated by the use of k-fold cross-validation

16

Datasets

❖ When subjective evaluation is involved:
- engage multiple assessors
  - to provide greater confidence
- agree a consistent marking protocol
  - several standards usually in use
- gather data from multiple sites
  - to compensate for local marking practice
  - to sample representative demographic population

❖ Engage a health statistician *before* you start

17

Complex Figure Copying Test

18

Example Patient Drawings

19

Subjective Mark Scheme

3: Diagonal Cross
8: Parallel Lines
9: Triangle
1: Cross
10: Line
7: Small Segment
11: Circle with 3 Dots
13: Triangle
4: Horizontal Line
16: Line
6: Small Rectangle
15: Line
14: Diamond
2: Large Rectangle
12: Parallel Lines
18: Square
5: Vertical Line
17: Cross

20

655

Choice of Evolutionary Algorithm

❖ Many to choose from

❖ Choice often based on:
  - previous experience
  - match to data representation
  - performance in previous similar applications

❖ Consider conventional statistical analysis
  - comparison of performance
  - justification for the use of an EA
 - understand the nature of the data

❖ Ensembles of EAs have potential

21

Cartesian Genetic Programming (CGP)

❖ Form of genetic programming
  - Miller and Thomson (1997)

❖ Genotype is a list of integers
 - that represent the program elements
  - how they are connected together

❖ Representation - a directed graph
  - simple, flexible and convenient for many problems

22

Example CGP Network

0 1 1   1 1 3   0 2 2   2 3 1   5

23

24

Implicit Context Representation

❖Consider standard GP

❖Parse tree structure

❖Mutation and crossover

25

Enzyme Genetic Programming
*(Lones and Tyrrell)*

26

27

## Implicit Context Representation for CGP

Mutation of components'

❖Binding sites' shapes

❖Function

28

657

Formation of Network

Inputs — Output — Available Components

29

Formation of Network

Inputs — Output — Available Components

30

Formation of Network

Inputs — Output — Available Components

31

Formation of Network

Inputs — Output — Available Components

32

Formation of Network

Data Input

❖Many different possible modalities, e.g.
- image
- continuous and discrete measurements
- text

Desired Output

- Often a two class problem – disease/no disease
  - Sometimes multiclass (typically 5)
- Requires thresholding of output or other approaches

Fitness Function

❖In clinical studies often based on sensitivity and specificity
- sensitivity = TP/P
- specificity = TN/N

Where:

TP number of true positive instances correctly classified

TN number of true negative instances correctly classified

P is number of positive instances that truly exist

N is number of negative instances that truly exist

Slide 37

Choice of Threshold Value

- Can be used to weight classification
- According to the cost associated with a misclassification
- Often summarised using ROC curves

TP

FP

TN

FN

100%

P(TP)

0%   P(FP)   100%

kakau. Released under the GNU Free Documentation License.

37

Slide 38

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes   Classifier   Output scale

Cancer

Non-cancer

True positive rate

1

0

0   False positive rate   1

38

Slide 39

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes   Classifier   Output scale

Cancer

Non-cancer

True positive rate

1

0

0   False positive rate   1

39

Slide 40

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes   Classifier   Output scale

Cancer

Non-cancer

True positive rate

1

0

0   False positive rate   1

40

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes **Classifier** **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

41

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes **Classifier** **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

42

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes **Classifier** **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

43

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes **Classifier** **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

44

Slide 45

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes   **Classifier**   **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

45

Slide 46

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

Input classes   **Classifier**   **Output scale**

Cancer

Non-cancer

True positive rate

False positive rate

Area Under Curve (AUC)

46

Slide 47

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

- Area Under Curve (AUC)
  – Probability of ranking a class member higher than a non-member
  – *i.e.* p[C(cancer)>C(non-cancer)]

True positive rate

False positive rate

Area Under Curve (AUC)

47

Slide 48

ROC Analysis

❖Receiver Operating Characteristic (ROC) curves:

- Area Under Curve (AUC)
  – Probability of ranking a class member higher than a non-member
  – *i.e.* p[C(cancer)>C(non-cancer)]
 – AUC of 0.5 equivalent to random classification
  – A classifier with AUC = n has the same power as one with AUC = 1-n
  – AUCs recently attracted criticism

True positive rate

False positive rate

Area Under Curve (AUC)

48

ROC Analysis

❖Multi-class ROC analysis:

- Hand and Till, 2001:

$$\text{AUC}_{\text{multiclass}} = \frac{2}{|C|(|C|-1)} \sum_{\{c_i, c_j\} \in C} \text{AUC}(c_i, c_j)$$

- ≈ mean of AUCs for each pair of classes
- Direction of AUCs (> or < 0.5) is important
  – i.e. must separate classes in the correct order

D. Hand and R. Till. A simple generalization of the area under the ROC curve to multiple class classification problems. *Machine Learning*, 45(2):171-186, 2001.

49

Case Example 1: Breast Cancer
(www.breastcanceruk.org.uk/statistics/2004-6)

❖207,000 women diagnosed in the US in 2010
- 40,000 died as a result of the disease
❖1 in 9 women will suffer from breast cancer at some time in their life
❖Most commonly diagnosed cancer in women under the age of 35
❖Accounts for some 25% of all cancer cases in women worldwide

50

Mammograms

❖Assessed subjectively
❖Size, shape and texture of
- microcalcifications
- spiculated masses

51

Microcalcifications

❖Calcium deposits
- secretions from ductal structures
❖Occur in clusters
❖40-50% cancerous
❖Discriminated by:
- shape
- size
- texture
- distribution

52

Microcalcifications

Example cluster of malignant microcalcifications

Example cluster of benign microcalcifications

(Images courtesy of the *Radiology Assistant:* www.radiologyassistant.nl)

53

Spiculated Masses

Example spiculated mass
(Image courtesy of the *Radiology Assistant:* www.radiologyassistant.nl)

54

Datasets

❖ Several publically available datasets of mammograms
  - Mammographic Image Analysis Society (MIAS) Database
  - University of South Florida Digital Mammography Database (USFDMD)
  - Lawrence Livermore/University of California (LLNL/UCSF) Database

❖ Many privately constructed datasets

55

Datasets

❖ All have their disadvantages
❖ Lack consistency in:
  - classification
  - demographic spread
  - diagnosis
  - supporting diagnostic information
  - digitization
  - resolution
  - file format

56

Using Existing Datasets

❖Using other peoples datasets may have implications!

❖LLNL/UCSF database

❖From "Somewhere in England"

Constructing a New Dataset

❖Requires:
- clinical cooperation
- authority
- suitable software tools
  – especially, the user interface

Regions of Interest (ROI)

❖ Regions showing microcalcifications are identified (128x128 pixel)
❖ These are divided into smaller sections called 'parts' (8x8 pixels)

8x8 pixels

Application of CGP

❖CGP as an optimizer

❖CGP as a feature extractor and classifier

CGP as an Optimizer

Hope, Smith and Munday [6]

Region of interest in mammogram   SGLD Matrix   CGP network

61

## Spatial Gray Level Dependence Matrix

❖ Also known as spatial gray co-occurrence matrix

❖ Considers positional information of pixels

❖ Following features from the SGLD matrices

- at 45°, 90°, 135° and 180°
- maximum value
- second moment
- third moment

62

CGP as Feature Extractor and Classifier

63

Walker, Völk, Smith and Miller [7]

64

Example Results

Additional Approaches

❖ Use OpenCV image functions as CGP function set (Simon Harding, CGP-IP)

Case Example 2: Parkinson's Disease

❖ Common, chronic, progressive neurodegenerative brain disease

❖ Affects the control of muscles

❖ Incidence of 1 person in 1000
  • about 1 person in 100 over the age of 60

❖ Insufficient formation and action of dopamine

Primary Symptoms of Parkinson's Disease

❖ Tremor
  • 3Hz-8Hz
❖ Rigidity
  • cogwheel
❖ Bradykinesia
  • slowing in movement
❖ Postural instability
  • poor balance

Conventional Diagnosis of Parkinson's Disease

❖Diagnosis of idiopathic Parkinson's Disease

- based on clinical features
- often very subjective
- poor sensitivity - up to 25% error in diagnosis
- PET scans to detect decreased dopamine activity

❖Medication

- L-dopa, artificial dopamine
- has limited life due to feedback inhibition
- eventually becomes counterproductive.

69

Computer-Based Assessment

❖Based on neuropsychological tasks

- figure copying tasks
- finger tapping tasks
- measurement of tremor at rest

❖Patient's movements digitised in real-time

70

Data Analysis

❖Initially, results poor

❖Closer inspection of patient data

- patients with Parkinson's disease
- controls with no known neurodegenerative condition

71

Typical Parkinson's Disease Patient FFT

72

Typical Control FFT

73

Problematic Control FFT

74

Figure-Copying Tasks

❖ Choice of task domain important

❖ Used to emphasize symptoms under consideration

75

Velocity Profile of Patient's Response

76

Identification of Features

❖Features unique to Parkinson's patients
  • determined through visual inspection

❖Indicates a two-stage acceleration

❖Consistent with hesitation
  • Bradykinesia?

77

Patient Measurements

Evolutionary Algorithm

78

Example Results

Age-matched Controls   Parkinson's Patients

79

Finger Tapping Task

80

Patient Measurements

Evolutionary Algorithm

Case Example 3: Thyroid cancer

Lones, Smith, Harris et al. [8]

❖ Incidence of 1 in 842 for men, 1 in 324 for women[*]

❖ 4 types, in order of increasing aggressiveness:

- **Papillary carcinoma**
  - 70-80% of cases, low mortality rate
- **Follicular carcinoma**
  - 10-15%, fairly low mortality rate
- **Medullary carcinoma**
  - 5-10%, moderate mortality rate
- **Anaplastic carcinoma**
  - <5%, high mortality rate

*UK Thyroid Cancer Statistics, Cancer Research UK, 2008.

Raman Spectroscopy

❖ Optical methodology
  • Uses monochromatic light
  • Measures energy states

❖ Advantages
  • Detailed
  • Fast
  • Non-invasive
  • Non-destructive
  • Uses small samples

❖ Disadvantages
  • Complex signals
  • Difficult to analyse

85

Biochemical Spectra

DNA and RNA bases   Amino acids

J. De Gelder, K. De Gussem, P. Vandenabeele and Luc Moens, Reference Database of Raman spectra of biological molecules, *Journal of Raman Spectroscopy* 38:1133-1147, 2007.

86

Thyroid Cell Lines

Class	Name	Cell Type	Samples
1	Nthy-ori 3-1	Normal follicular epithelial	30
2	K1	Papillary thyroid carcinoma	25
3	RO82-W-1	Follicular thyroid carcinoma	25
4	TT	Medullary thyroid carcinoma	24
5	8305C	Anaplastic thyroid carcinoma	25

87

Methodology

❖ Evolve classifiers
  • Terminal set: Raman offsets {600,…,1800}
  • Function set: +, -, *, mean, min, max, negate

❖ Using implicit context representation CGP [Smith, 2005]
  • Cartesian Genetic Programming [Miller and Thomson, 2000]
  • Implicit context representation [Lones and Tyrrell, 2002]

❖ Fitness is the ability to separate cancer classes
  • In order of biological aggressiveness
  • Measured using multi-class area under ROC curve

S. Smith et al. An implicit context representation for evolving image processing filters, *EvoIASP 2005*.
J. Miller and P. Thomson, Cartesian genetic programming, *EuroGP 2000*.
M. Lones and A. Tyrrell, *Genetic Programming and Evolvable Machines* 3(2):193-217.

88

Results

All runs

Best run

Classes	Train	Validate	Test
1/2/3/4/5	**0.75**	**0.78**	**0.75**
1/2	0.69	0.64	0.61
1/3	**0.80**	**0.83**	0.74
1/4	**0.85**	**0.94**	**0.88**
1/5	**0.94**	**0.98**	**0.91**
2/3	0.65	0.69	0.62
2/4	0.70	**0.82**	**0.79**
2/5	**0.84**	**0.89**	**0.83**
3/4	0.59	0.65	0.71
3/5	**0.76**	**0.76**	**0.78**
4/5	0.68	0.62	0.60

Results

ROC curves for highest scoring classifier

(a) Normal/Papillary (b) Normal/Follicular (c) Normal/Medullary (d) Normal/Anaplastic (e) Papillary/Follicular

(f) Papillary/Medullary (g) Papillary/Anaplastic (h) Follicular/Medullary (i) Follicular/Anaplastic (j) Medullary/Anaplastic

---

Results

The 10 highest scoring classifiers

Expression	Test AUC
$out = \overline{\{885, 1001\}} - 1607 - \max\{1656, 1117\}$	0.75
$out = (841 + 1002) - (836 + 1600) + (\max\{-622, 1657 * 1655\} - 1657 * 1655)$	0.75
$out = 780 - 1606 + (\max\{1002, 1084\} - (636 + 1664))$	0.74
$out = (1002 - 1661) - ((1607 - 1379)(625 - 1783)) - \max\{625, 636\}$	0.73
$out = -(\overline{\{-1001, 1270 + 1741\}} + \overline{\{-999, 1606\}})$	0.72
$out = -(-\overline{\{1002, 999\}} + \overline{\{-1473, 1173\}} - -1473 * (1599 + 723))$	0.72
$out = (636 * 1661 - \max\{878, 893\})(636 * 1661 - (1002 - 833))$	0.72
$out = -\{sub_1, \min\{833, \overline{\{1463, 636\}}\}, sub_1, 1603 + 1661\}$ $sub_1 = -\max\{1685, 1002\}$	0.71
$out = (1001 - 713) + (1715 * 1751 - 636)$	0.71
$out = \overline{\{(1439 + \overline{\{1533, 1759\}})^2, sub_1 - sub_2\}} + (sub_1 - sub_2)$ $sub_1 = 1603 + 1757 + (833 - 1001)$ $sub_2 = \overline{\{1566, 964\}}$	0.71

Results

Raman shifts referenced by the 10 highest scoring classifiers

Results

Phenylalanin

Amide I

RNA/DNA bases

Aromatic amino acids

Experimental Settings

❖ 50 runs, 50 generation limit, population of 500
❖ CGP grid size of 5x5
❖ Using training, validation and test sets

Function	Description
x + y	Returns the sum of its inputs
x − y	Returns the difference of its inputs
x * y	Returns the product of its inputs
$\overline{\{x,y\}}$	Returns the mean of its inputs
min{x,y}	Returns the lesser of its inputs
max{x,y}	Returns the greater of its inputs
-x	Returns its input multiplied by -1

Overview

Cell sample   Raman spectrum   Evolved classifier   Classifier output

Anaplastic
Medullary
Follicular
Papillary
Normal

Planning Your Own Study

❖ Determine the *real* clinical need
  • and the potential for commercilasation
❖ Identify clinical collaborators
❖ Design a clinical protocol
❖ Protect intellectual property
❖ Apply for ethical approval
❖ Obtain regulatory compliance
❖ Undertake clinical studies
❖ Processing data

Determine the Real Clinical Need

❖ *Not* searching for a need for the technology you have developed
❖ Speak to the users
  • doctors, nurses and patients
❖ Try to evaluate:
  • improved quality of life
  • cost savings/other benefits

Potential for Commercialisation

❖ Consider commercialiation at the outset
  • establish what is needed and will be useful
  • gets the technology to the patient
  • raises funding for development
    – and further research
❖ The process itself can have value

Identifying Clinical Collaborators

❖ Essential for:
  • data
  • establishing the justification of the work
  • obtaining sufficient patient numbers
  • obtaining clinical acceptance
  • provide clinical interpretation of results

Designing a Clinical Protocol

❖ Should be clinically led
  • beware of mission creep/other clinical interests
  • needs to establish ground truth through conventional clinical tests
  • consider engaging a clinical trial unit
❖ Principal and secondary research questions
❖ Participant sample size
  – with statistical justification
❖ Inclusion/exclusion criteria
❖ End points

Datasets

❖If using existing data determine its:
- suitability
- integrity

❖If no existing datasets available
- need to acquire patient measurement
- ethical approval required
- sensors may also require regulatory approval

101

Applying for Ethical Approval

❖Scientific justification
❖Clinical protocol
❖Participant recruitment procedures
– participant information sheet
•informed consent
❖Research may need to undergo external review

102

Protect Intellectual Property

❖Not as difficult as it sounds!
- initial filing
- PCT
- International Phase
❖Engage a good patent attorney
❖Essential for getting attention
- and securing further funding

103

Regulatory Compliance

❖Consider then need for regulatory compliance
❖Sometimes required to undertake clinical studies
- required before sales can begin
- often based on self-certification
❖Different regulatory bodies for different countries
- all based on same ISO standards

104

Undertake Preliminary Clinical Studies

❖Small proof of concept study
- validates the technology
- helps determine the clinical need
- highlights problems/modifications
- gains supporters/champions

105

Analysing Data

❖Choose an appropriate algorithm
❖Consider adopting clinically accepted measures
❖Use k-fold cross-validation when dealing with small patient numbers
❖Ensembles can be effective in increasing classification performance

106

Avoid Common Pitfalls

❖Don't touch the patients (or their data)!
- until you have the necessary ethical approval/consent
- and possibly other statutory authority

❖Be careful what you offer
- work takes time and consultants can be demanding!

❖Expect to do all the running
- medics are busy
- many not be used to applying for grants
- or writing long papers

107

Useful Resources

❖Books

108

Useful Resources

❖Journals

- IEEE Transactions on Evolutionary Computation
- Genetic Programming and Evolvable Machines
- IEEE Transactions on Neural Systems and Rehabilitation Engineering
- BioSystems
- International Journal of Computers in Healthcare

Useful Resources

❖Conferences

- IEEE Symposium Series on Computational Intelligence (SSCI) Workshop on Computational Intelligence in Medical Imaging (CIMI)

- Genetic and Evolutionary Computation Conference (GECCO) Medical Applications of Genetic and Evolutionary Computation (MedGEC)

Possible Benefits

❖More publications
- in engineering and medical journals

❖More funding sources
- government grants
- basic & applied research and knowledge transfer
- charities
- patents and spin-out companies!

❖More fun!

Summary

❖Medical applications of EC rely on:
- good collaborations
- good data
- appropriate evolutionary algorithms

References

1. Leonardo Bocchi. 2003. Multiple genetic snakes for bone segmentation. In Proceedings of the 2003 international conference on Applications of evolutionary computing (EvoWorkshops'03), Stefano Cagnoni, Colin G. Johnson, Elena Marchiori, David W. Corne, and Jens Gottlieb (Eds.). Springer-Verlag, Berlin, Heidelberg, 346-356.

2. Gabriel Mañana, Fabio González, and Eduardo Romero. 2005. Distributed genetic algorithm for subtraction radiography. In *Proceedings of the 2005 workshops on Genetic and evolutionary computation* (GECCO '05). ACM, New York, NY, USA, 140-146. DOI=10.1145/1102256.1102288 http://doi.acm.org/10.1145/1102256.1102288

3. Ghannad-Rezaie, M., Soltanian-Zadeh, H., Siadat, M.-R. and Elisevich, K.V. 2006. Medical data mining using particle swarm optimization for temporal lobe epilepsy. IEEE Congress on Evolutionary Computation (CEC) 2006, pp. 761–768.

4. Alderliesten, T., Bosman, P.A.N., Niessen, W.J. 2007. "Towards a Real-Time Minimally-Invasive Vascular Intervention Simulation System," Medical Imaging, IEEE Transactions on, vol. 26, no. 1, pp. 128–132, doi: 10.1109/TMI. 2006.886814 URL: http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=4039522&isnumber=4039521

5. Koutsojannis, C. and Hatzilygeroudis, I. 2006. Fuzzy-evolutionary synergism in an intelligent medical diagnosis system. Knowledge-Based Intelligent Information and Engineering Systems. 10th International Conference, KES 2006. Proceedings, Part II. Lecture Notes in Artificial Intelligence, Vol. 4252. Springer-Verlag, pp. 1305–1312.

6. D. Hope, S. Smith, and E. Munday, "Evolutionary algorithms in the classification of mammograms," in IEEE Symposium on Computational Intelligence in Image and Signal Processing, pp. 258–265, 2007.

7. J.Walker, K. Völk, S. Smith, and J. Miller, "Parallel evolution using multi-chromosome Cartesian genetic programming," Genetic Programming and Evolvable Machines, vol. 10, no. 4, 2009.

8. M. A. Lones, S. L. Smith, A. T. Harris, A. S. High, S. E. Fisher, D. A. Smith and J. Kirkham, "Discriminating Normal and Cancerous Thyroid Cell Lines using Implicit Context Representation Cartesian Genetic Programming," Proc. World Congress on Computational Intelligence (WCCI) 2010, Barcelona, IEEE Press, 2010.